Eli Lilly said sales of weight loss drug Zepbound and diabetes treatment Mounjaro surged in the first quarter.
Eli Lilly & Co. is suing four telehealth companies selling compounded versions of Lilly's weight-loss drug Zepbound and its diabetes drug Mounjaro.
The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.
The Biden administration proposal would have significantly expanded access to obesity to millions of Americans but would have cost the government billions.
Hims & Hers is adding Zepbound, Mounjaro, and the generic injection liraglutide to its platform.
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
Telehealth firms Teladoc and LifeMD said they signed an agreement with Eli Lilly's pharmacy partner to offer patients the weight-loss drug, Zepbound.
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.
Eli Lilly is offering higher-dose vials through its direct-to-consumer website, LillyDirect, which started offering lower doses in vials in August.